Enucleation Of Prostate — Cost, Top Hospitals & Success Rates | MyMedicPlus

Enucleation of the prostate is a surgical technique for treating benign prostatic hyperplasia (BPH) — abnormal non-cancerous enlargement of the prostate gland — by removing the obstructing adenoma (the inner zone of prostatic tissue compressing the urethra) from within its surgical capsule, rather than simply coring out or ablating the tissue as in traditional transurethral resection of the prostate (TURP). The most established and evidence-based enucleation technique is holmium laser enucleation of the prostate (HoLEP), which uses a holmium:YAG laser to precisely dissect the adenoma from the outer surgical capsule layer by layer, harvesting the tissue intact into the bladder where it is morcellated (chopped into small pieces) and suctioned out — resulting in complete removal of the obstructing prostatic tissue.

HoLEP was developed in the 1990s by Peter Gilling and Mark Fraundorfer in New Zealand and has since been adopted by urological centres worldwide as the gold standard endoscopic treatment for BPH of any prostate size, with a particularly important role for very large glands (over 80–100 grams) where open prostatectomy was previously the only surgical alternative. The procedure is entirely transurethral — no skin incisions are required — using a specialised laser resectoscope introduced through the urethra under general or spinal anaesthesia.

Alternative prostate enucleation techniques include thulium laser enucleation (ThuLEP), diode laser enucleation, green light laser enucleation, bipolar enucleation of the prostate (BipolEP), and robotic waterjet ablation (Aquabeam). All share the same anatomical principle of enucleating the adenoma from its surgical capsule, differing primarily in the energy source and instrumentation used. These size-independent techniques have effectively replaced open simple prostatectomy for large prostates at most major urological centres.

Prostate enucleation treats benign prostatic hyperplasia (BPH) causing lower urinary tract symptoms (LUTS) — a collection of obstructive and irritative voiding symptoms including poor urinary stream, straining, hesitancy, incomplete bladder emptying, urinary frequency, urgency, and nocturia (waking at night to urinate). BPH is extremely common in men over 50 and affects approximately 50% of men by age 60 and 80% by age 80, though only a minority develop significant obstructive symptoms requiring surgical intervention.

Surgical treatment is indicated when LUTS are moderate to severe (International Prostate Symptom Score IPSS above 8), cause significant quality-of-life impairment, and have not been adequately managed by pharmacological therapy (alpha-blockers, 5-alpha-reductase inhibitors, or combination). Absolute surgical indications — warranting prompt intervention regardless of symptom severity — include acute urinary retention (inability to pass urine requiring catheterisation), recurrent urinary tract infections from poor bladder emptying, bladder stones from residual urine, recurrent haematuria from prostatic vascularity, and renal impairment from obstructive uropathy (high-pressure retention causing upper urinary tract damage).

HoLEP is size-independent — suitable for prostates of any size from small (30 grams) to very large (over 500 grams), making it the preferred technique for large prostate glands where standard TURP is limited by operating time and fluid absorption risk. Men with any prostate size who have failed or declined medical treatment and have significant BPH symptoms or complications are candidates. Men on anticoagulants or antiplatelet medications may be at slightly higher risk of bleeding complications, though HoLEP's laser haemostatic properties make it more appropriate for anticoagulated patients than conventional TURP.

Contraindications to HoLEP include active urinary tract infection requiring treatment before surgery, significant urethral stricture limiting scope passage (requires dilation or urethroplasty before enucleation), and uncorrectable coagulopathy. Men with prostate cancer (as the primary surgical concern) are not appropriate for enucleation — prostate cancer requires cancer-specific surgery (radical prostatectomy) or radiotherapy. Preoperative flexible cystoscopy and prostate-specific antigen (PSA) measurement help exclude malignancy. Men with neurogenic bladder dysfunction may not achieve full symptom benefit from prostate surgery, as their voiding dysfunction has a central nervous system cause beyond the outflow obstruction.

HoLEP is performed with the patient in the lithotomy position (lying on their back with legs elevated) under spinal or general anaesthesia. A specialised continuous-flow laser resectoscope (24–26 French diameter) is introduced through the urethra. The holmium laser (2,100 nm wavelength) is used to make initial incisions at the 5 and 7 o'clock positions at the bladder neck, defining the lateral lobes of the adenoma. The laser progressively dissects each adenomatous lobe from the underlying surgical capsule in a systematic, anatomical plane — analogous to peeling the adenoma away from its 'shell.' Each enucleated lobe is pushed into the bladder. A tissue morcellator — a high-speed rotating blade inserted through the resectoscope — chops the adenoma in the bladder into small fragments suctioned into the suction unit, while the flexible morcellator tip safely avoids the bladder wall.

Thulium laser enucleation (ThuLEP) uses a thulium:YAG laser with similar technique and comparable outcomes to HoLEP. Bipolar enucleation (BipolEP) uses bipolar radiofrequency energy in saline irrigation rather than a laser, offering a more accessible technique for surgeons unfamiliar with laser enucleation. Aquabeam (robotic waterjet ablation) uses an ultra-high pressure saline jet guided by real-time transrectal ultrasound and AI-assisted image analysis to ablate the prostatic adenoma in a single application, though it is not technically an enucleation and is limited to prostates under 150 grams. Open simple prostatectomy (Millin's retropubic or transvesical approach) remains an option for very large prostates (over 150–200 grams) in centres without HoLEP expertise, though HoLEP with morcellation handles even very large glands at experienced centres.

HoLEP achieves the most complete and durable relief of bladder outlet obstruction of any endoscopic BPH procedure. The complete anatomical removal of the obstructing adenoma — unlike TURP which removes tissue piecemeal and leaves residual tissue — means that HoLEP has virtually no tissue regrowth, with symptom recurrence rates of under 2% at 10 years compared to 15–20% re-treatment rates for TURP over the same period. This durability makes HoLEP the definitive, single-lifetime treatment for BPH in most patients.

Improvement in IPSS (International Prostate Symptom Score) is dramatic after HoLEP: mean pre-operative IPSS of 20–24 (severe) typically improves to 4–6 (mild) at 6 months. Peak urinary flow rate (Qmax) improves from typical pre-operative values of 6–10 mL/s to 25–30 mL/s post-HoLEP. Quality of life scores improve commensurately. Blood transfusion requirement is under 1% — significantly lower than TURP (1–3%) or open prostatectomy (5–10%) — reflecting the excellent haemostatic properties of holmium laser. HoLEP is considered size-independent (equally effective regardless of prostate volume), catheter-independent (shorter catheterisation time than TURP or open surgery), and suitable for anticoagulated patients with reduced dose modification required.

HoLEP carries a specific complication profile distinct from conventional TURP. Stress urinary incontinence — leakage of urine with coughing, sneezing, or exercise from external urinary sphincter damage — occurs transiently in 10–30% of patients in the early post-operative period (first 3 months), resolving in the majority with pelvic floor exercises by 12 months. Permanent stress incontinence requiring further treatment occurs in approximately 1–2% of cases. This risk is higher in HoLEP than TURP due to the more complete tissue enucleation and closer dissection to the sphincter mechanism, requiring careful intraoperative sphincter identification and preservation.

Bladder neck contracture (scarring at the junction of the bladder and urethra) occurs in approximately 2–3% of cases and may require endoscopic incision (bladder neck incision) or dilation. Urinary tract infection occurs in approximately 5–10% of patients post-operatively and is managed with antibiotics. Retrograde ejaculation — backward ejaculation into the bladder during orgasm rather than antegrade emission — is nearly universal (90–95%) after HoLEP and all endoscopic prostate procedures, as the internal urethral sphincter at the bladder neck is disrupted during surgery. This does not affect erection or orgasm but does render the patient unable to father children via normal intercourse, which must be explicitly discussed before surgery with men of reproductive age. Perforation of the capsule or bladder (requiring conversion to open surgery) is rare at under 1%.

Following HoLEP, a urethral catheter is placed during surgery and typically removed at 24 hours post-operatively — significantly earlier than after TURP (48–72 hours) or open prostatectomy (5–7 days). Most patients are able to pass urine satisfactorily after catheter removal, with some experiencing temporary urgency, frequency, and dysuria for 4–6 weeks as the bladder adjusts. Haematuria (blood in the urine) is expected for the first 1–2 weeks and usually resolves spontaneously; patients should maintain a high fluid intake (2–3 litres per day) to dilute the urine and reduce clot formation.

Pelvic floor exercises (Kegel exercises) are commenced immediately after catheter removal and continued for 3 months to minimise the risk of stress urinary incontinence. Return to light activity (walking, desk work) is possible within 2 weeks; vigorous exercise, heavy lifting, and sexual activity are restricted for 4–6 weeks. Follow-up at 6 weeks assesses IPSS improvement, urinary flow rate (uroflowmetry), and post-void residual volume by ultrasound. PSA measurement 3–6 months post-HoLEP documents the expected PSA decline (typically 50–70% reduction from pre-operative level) and establishes a new baseline for future prostate cancer surveillance.

HoLEP costs more than standard TURP due to the specialised holmium laser generator and reusable laser fibre costs, tissue morcellator requirement, and the subspecialty training needed. In the US, HoLEP at a hospital or ambulatory surgery centre costs USD 12,000–25,000 inclusive of surgeon fees, anaesthesia, and hospital charges. Standard TURP costs USD 8,000–18,000. Insurance covers BPH surgery for medically indicated cases with documented failed medical management. In the UK, NHS TURP and HoLEP services are available, though waiting times for HoLEP at specialist centres may be longer.

For patients seeking surgical BPH treatment internationally, India and Thailand are leading medical tourism destinations for urological procedures. HoLEP at specialist urology centres in India (Apollo, Fortis, Max, Medanta) costs USD 2,000–4,000 all-inclusive. Thailand (Bumrungrad International, Bangkok Pattaya Hospital) offers HoLEP for USD 2,500–5,000. Turkey offers costs of USD 2,500–4,500. Standard TURP in India costs USD 1,200–3,000. These savings of 70–80% versus US costs, combined with India's internationally trained urologists and comprehensive postoperative follow-up, make India the leading destination for BPH surgery for international patients.

Standard transurethral resection of the prostate (TURP) — long considered the gold standard BPH procedure — uses electrical resection loops to excise prostate tissue and remains widely performed. While its short-term outcomes are equivalent to HoLEP, TURP has higher re-treatment rates at 10 years, higher blood transfusion rates, and is limited to prostates under 60–80 grams due to TURP syndrome risk from absorption of hypotonic irrigant. Greenlight laser photoselective vaporisation of the prostate (PVP) uses a 532 nm potassium-titanyl-phosphate (KTP) or lithium triborate (LBO) laser to vaporise prostatic tissue and offers good haemostatic properties and earlier catheter removal, though with higher tissue regrowth rates than HoLEP at 5 years.

Medical management with alpha-blockers (tamsulosin, alfuzosin, doxazosin, silodosin) improves LUTS by relaxing smooth muscle in the prostate and bladder neck; 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce prostate volume by 20–25% over 6 months by inhibiting testosterone conversion, and their combination reduces the risk of BPH progression and surgery over 5 years compared to monotherapy. Minimally invasive therapies including UroLift (permanent implants mechanically lifting and retracting the prostate lobes), Rezum (steam ablation using water vapour convective energy delivery), and iTind (temporarily implanted nitinol device reshaping the prostatic urethra) offer alternatives to surgery for selected patients, with faster recovery but less definitive outcomes than HoLEP.